Study S001107

A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of JY09 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

ClinicalTrials.gov record

Registration

Registration: NCT06254014
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 270
Start: 2024-07-10
Primary completion: 2026-05-01
Lead sponsor: Beijing Dongfang Biotech Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Exendin-4 Fc fusion protein injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [Baseline, Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.